Previous 10 | Next 10 |
2023-09-29 04:38:46 ET More on Vaccinex Financial information for Vaccinex For further details see: Vaccinex slumps 29%, prices $9.6M equity
ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4...
2023-09-28 12:59:55 ET Gainers: Baudax Bio ( BXRX ) +75% . Chico's Fas ( CHS ) +63% . Aytu BioPharma ( AYTU ) +35% . Axcella Health ( AXLA ) +35% . Vaccinex ( VCNX ) +33% . Organogenesis Holdings ( ORGO ) +27% . F...
Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select specific antibody-producing cells Successfully applied in proof-of-concept ev...
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb ® application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT) conference ROCHESTER, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Vaccinex,...
2023-09-26 13:46:32 ET Gainers: Soleno Therapeutics ( SLNO ) +446% . Femasys ( FEMY ) +271% . Immunovant ( IMVT ) +101% . Intercept Pharmaceuticals ( ICPT ) +79% . Acasti Pharma ( ACST ) +35% . Applied Therapeutics ( APLT ...
"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer’s Disease Conference to be held in Boston on October 24-27, 2023. “Inhibition of...
2023-09-22 16:40:09 ET More on Vaccinex Financial information for Vaccinex For further details see: Vaccinex implements reverse stock split to regain Nasdaq compliance
ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-15 reverse...
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) ...
News, Short Squeeze, Breakout and More Instantly...
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, I...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...
Vaccinex, Inc. (NASDAQ: VCNX) is one of today's top gainers. The company's shares have moved 15.16% on the day to $6. Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet...